The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study. 

The Phase IIa dose expansion ModiFY study is evaluating the safety, tolerability, and preliminary efficacy of Modi-1 in combination with checkpoint inhibitors (CPIs) in patients with renal and head and neck cancers. 

The cohort investigating HPV negative head and neck squamous cell carcinoma (SCCHN) was designed to determine if the overall objective response rate (ORR) in patients could be improved by combining Modi-1 Moditope in combination with standard of care single agent checkpoint inhibitor pembrolizumab.  

Three of the seven evaluable patients that have received immunisation with Modi-1 Moditope combined with a checkpoint inhibitor demonstrated a partial response as determined by RECIST 1.1 tumour assessment at their 25-week scan.  

This equates to an ORR of 43% compared to historical ORRs of 19% for pembrolizumab and 13% for nivolumab. 

Chief Investigator Christian Ottensmeier, Professor of Immuno-Oncology at Head and Neck Institute, University of Liverpool, commented: “This positive preliminary clinical read-out validates the scientific rationale for Moditope vaccines as a therapy with real potential to improve outcomes achievable with checkpoint inhibitors alone. Given its good safety profile and ease of use, I remain keen to continue using this vaccine as well as explore the application of Modi-1 in the neoadjuvant setting.” 

The US Patent and Trademark Office (USPTO) has granted a patent for Moditope, already granted by the European Patent Office, along with China, Japan and Australia.

Diana Spencer, Senior Digital Content Editor, DDW